Book a Demo

Please select a preferred date(s) and time(s):

    Contact Sales

      By clicking "Submit" you agree to our Privacy Policy

      CertiScan®: Adherence Matters

      Case Study

      Evaluating Hepatitis C Treatment in Phase 4 Trials

      5 May 2024
      When an international team needed a precise way to measure adherence, they turned to Med-ic smart blister packages. Their findings have practical clinical applications, and also demonstrate the advantages of smart packages versus clinical pill counts or participant self-reports.
      Evaluating Hepatitis C Treatment in Phase 4 Trials


      Direct-Acting Antiviral (DAA) therapy is an effective treatment for hepatitis C. However DAA is expensive, and patients who use drugs or alcohol face barriers to accessing DAA. With the support of AbbVie and Gilead, an international team sought to understand the patterns of drug and alcohol usage and their impacts on DAA usage, including factors associated with nonadherence and the impact of adherence on Sustained Virologic Response (SVR). They carried out 2 international, multicenter, open-label, single-arm, phase 4 trials: D3FEAT and SIMPLIFY.


      The majority of studies evaluating adherence among people with recent injection drug use or receiving opioid agonist treatment had used imprecise methods for measuring adherence.


      Med-ic smart blister packages were used to track dose dates and times. These Med-ic packages were custom designed and fit-for-purpose: they contained 1 tablet per day in a single blister in SIMPLIFY, and 3 tablets in individual blisters for the morning dose and 1 tablet in a single blister for the evening dose in D3FEAT. Participants received AUS$10 (or equivalent) to return each blister pack. Adherence was also measured by counting remaining pills in the returned blister packs (clinical pill count) and through self-reported adherence questionnaires every 4 weeks. Participants completed a self-administered questionnaire on a tablet computer at enrollment, at treatment commencement, and every fourth week during treatment.


      The use of Med-ic smart blister packs for adherence monitoring was a major strength of this study, allowing for detailed and accurate adherence measurement over time, providing a more precise estimate of the effect of time on nonadherence.

      Using Med-ic and IMC solutions, the researchers were able to reach the following conclusions:

      1. This study demonstrated high adherence to once and twice-daily DAA therapy among people with recent with recent injection drug use or receiving opioid agonist treatment.
      2. The observed nonadherence did not impact treatment or outcomes, suggesting forgiveness to nonadherence.
      3. These data are important to inform clinical guidelines, clinical management, and health policy, particularly in settings where there are restrictions for the reimbursement of DAA therapy for people who inject drugs.
      4. Blister pack measurement of adherence remains a more robust method of measuring adherence compared to clinical pill count or self-report

      Interested in learning more about this case? <a href="/contact-us">Contact us</a>.

      Recent Articles

      Scientific Publications | 16 May 2024

      Independent Study finds eCap™…

      Read More
      Press Releases | 6 May 2024

      Information Mediary Corp. and…

      PRESS RELEASE May 6, 2024 – New York, NY — Information Mediary Corp (IMC)…

      Read More
      Blog | 5 May 2024

      Welcome to the new…

      We are thrilled to unveil our revamped website! As you explore our new digital…

      Read More
      Case Studies | 5 May 2024

      Evaluating Hepatitis C Treatment…

      Overview Direct-Acting Antiviral (DAA) therapy is an effective treatment for hepatitis C. However DAA…

      Read More
      Whitepapers | 5 May 2024

      Driving Adherence With Smart…

      Read More
      Press Releases | 4 May 2024

      IMC introduces CertiScan® 2.0

      Att: Health Tech Desk FOR IMMEDIATE RELEASE April 28, 2021 New York, NY Contact:…

      Read More

      Let's Talk

      Our mission is to create adherence-focused technologies that enable safer, faster, more efficient, and more innovative clinical research. There’s an IMC solution that will transform your next trial. Don’t wait, start the conversation with our team now. We’ll reach out in order to:
      • Deeply understand your particular needs.
      • Explore how Med-ic®, eCap™, and CertiScan®, can benefit your study.
      • Work collaboratively to prepare a specific solution that will exceed your expectations.

      Connect with Us

        By clicking "Submit" you agree to our Privacy Policy